<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04298229</url>
  </required_header>
  <id_info>
    <org_study_id>200017</org_study_id>
    <nct_id>NCT04298229</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Dapagliflozin in Acute Heart Failure</brief_title>
  <acronym>DICTATE-AHF</acronym>
  <official_title>A Randomized, Open-label Study of Dapagliflozin in Patients With Type 2 Diabetes Admitted With Acute Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized trial of the addition of dapagliflozin to patients with diabetes
      hospitalized with acute decompensated heart failure (ADHF). Participants will be recruited
      following an initial standard evaluation in the ED and randomized within 24 hours of
      presentation for ADHF in a 1:1 fashion to protocolized diuretic therapy or dapagliflozin +
      protocolized diuretic therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with acute decompensated HF (ADHF) are generally admitted due to symptoms of
      congestion and 90% are treated with a loop diuretic. However at least one-third of these
      patients are inadequately decongested due primarily to &quot;diuretic resistance&quot; and/ or
      &quot;cardiorenal syndrome&quot;. The inability to achieve decongestion is associated with a worse
      prognosis and a higher rate of re-hospitalization for ADHF. More than 40% of all patients
      admitted with ADHF have diabetes and that percentage is growing both in Heart Failure with
      Reduced Ejection Fraction (HFrEF) and Preserved Ejection Fraction (HFpEF).

      The admission blood glucose is elevated in approximately one-half of ADHF hospitalizations.
      We recently demonstrated the admission blood glucose was within 50mg/dl of the chronic
      average blood glucose in 66% of patients with diabetes admitted with ADHF. The median (IQR)
      admission blood glucose change from the chronic blood glucose was only -7 (-29, 26) mg/dl.
      Thus, the acute glucose in patients with T2DM presenting with acute heart failure is most
      often related to poor chronic glucose control suggesting that these patients would benefit
      from attempts to initiate therapies to improve chronic glucose control while in the hospital.

      No new therapies have been introduced in the United States for ADHF in several decades.
      Natriuretic peptides such as nesiritide and ularitide have failed to improve outcomes in
      either the chronic or acute heart failure patients. Diuretic resistance and hyperglycemia are
      common problems in ADHF admissions and represent a therapeutic opportunity for new therapies.

      The sodium-glucose cotransporter-2(SGLT2) inhibitors, now approved for the anti-hyperglycemic
      therapies also have an osmotic diuretic and natriuretic effect. In the chronic setting SGLT2
      inhibitors reduce weight with modest decrements in systolic and diastolic blood pressure with
      a marked drop in albuminuria and a small drop in estimated GFR (-5 mL min-1.1.73 m-2) which
      returns to baseline over time. In patients with diabetes the SGLT2 transporter likely
      accounts for as much as 14% of total sodium chloride absorption. In the acute setting
      following a single dose, SGLT2 inhibitors did not increase urine volume. However, the acute
      diuretic effects have not been studied in a population with heart failure with or without
      concomitant hyperglycemia who are undergoing diuresis. To our knowledge, no current trials
      are investigating the effects of SGLT2 inhibition in ADHF. The current studies planned in HF
      are investigating the acute effects of SGLT2 on stable HF (NCT03027960), the chronic effects
      of SGLT2 inhibition in compensated, chronic HF (NCT03619213, NCT02653482, NCT03030235,
      NCT03057977), changes in pulmonary pressure hemodynamics in patients monitored by CardioMEMs
      devices (NCT03030222), and effects on cardiopulmonary exercise fitness in chronic HF
      (NCT02862067).

      Congestion remains the major cause of hospital readmission for heart failure and an inpatient
      plan of care that allowed more effective decongestion would be rapidly and widely adopted by
      the medical community. Therefore, we propose to test the decongesting effects of the SGLT2
      inhibitor dapagliflozin in patients with Type II diabetes admitted with an acute
      decompensation of chronic heart failure.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be recruited following an initial standard evaluation in the ED and randomized within 24 hours of presentation for ADHF in a 1:1 fashion to protocolized diuretic therapy or dapagliflozin + protocolized diuretic therapy.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>The Clinical Event Adjudication Committee will consist of 3 independent clinicians, which will consist of at least one endocrinologist and at least one heart failure specialist. The members of this committee will be independent of the study implementation teams and will be blinded to study arm assignment. This committee will review abstracted clinical data to determine when primary endpoints and major events have occurred. The CEAC will review data for the following study outcomes:
Potential inhospital worsening heart failure events
30-day readmission events for heart failure or diabetes-related care
Prolonged hospitalization as a result of the following safety outcomes: hypotension requiring medical intervention or hypoglycemia requiring medical intervention</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative change in weight (kilograms)</measure>
    <time_frame>Baseline to Day 5 or discharge if earlier</time_frame>
    <description>cumulative change in weight (kilograms) per 40mg of IV furosemide equivalents from enrollment to day 5 or discharge (if earlier) between protocolized diuretic therapy and dapagliflozin plus protocolized diuretic therapy guided by urine output</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of worsening heart failure</measure>
    <time_frame>Baseline to hospital discharge, an average of 5 days</time_frame>
    <description>Incidence of worsening heart failure during hospitalization requiring IV inotropic therapy with dobutamine, milrinone, or dopamine or admission to an intensive care unit as adjudicated by the Clinical Event Adjudication Committee</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital readmission</measure>
    <time_frame>Day 30</time_frame>
    <description>Hospital readmission within 30 days of discharge for heart failure or diabetic reasons as adjudicated by the Clinical Event Adjudication Committee</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Heart Failure</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Protocolized diuretic therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patient will receive standard of care point of care blood glucose monitoring 4 times daily (before meals and at bedtime) and sliding scale insulin.
The initial loop diuretic regimen after enrollment:
Loop diuretic naïve: If the patient does not take a scheduled loop diuretic as an outpatient, the initial IV loop diuretic dose will be 40mg of furosemide equivalents every 12 hours.
Chronic, oral loop diuretic therapy: If the patient takes a scheduled loop diuretic regimen as an outpatient prior to hospital admission, the initial IV loop diuretic daily dose will be 2 times the total daily home regimen dose. Diuretic therapy will be titrated to goal urine output using a standardized diuretic protocol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Protocolized diuretic therapy plus SGLT2 inhibitor therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patient will receive standard of care point of care blood glucose monitoring 4 times daily (before meals and at bedtime) and sliding scale insulin.
The initial loop diuretic regimen after enrollment:
Loop diuretic naïve: If the patient does not take a scheduled loop diuretic as an outpatient, the initial IV loop diuretic dose will be 40mg of furosemide equivalents every 12 hours.
Chronic, oral loop diuretic therapy: If the patient takes a scheduled loop diuretic regimen as an outpatient prior to hospital admission, the initial IV loop diuretic daily dose will be 2 times the total daily home regimen dose. Diuretic therapy will be titrated to goal urine output using a standardized diuretic protocol.
The patient will receive SGLT2 inhibitor therapy with dapagliflozin 10 mg orally once daily until 5 days or hospital discharge.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin 10 MG</intervention_name>
    <description>SGLT2 inhibitors being investigated for its diuretic and natriuretic effects on top of protocolized diuretic therapy.</description>
    <arm_group_label>Protocolized diuretic therapy plus SGLT2 inhibitor therapy</arm_group_label>
    <other_name>sodium-glucose cotransporter-2(SGLT2) inhibitors</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Protocolized Diuretic Therapy</intervention_name>
    <description>Structured usual care arm with protocolized diuretic therapy based on urine output.</description>
    <arm_group_label>Protocolized diuretic therapy</arm_group_label>
    <arm_group_label>Protocolized diuretic therapy plus SGLT2 inhibitor therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age of 18 years or older

          -  Randomized within 24 of presentation during a hospital admission for hypervolemic
             decompensated heart failure defined as:

               -  pulmonary artery catheterization with a pulmonary capillary wedge pressure
                  greater than 19mmHg plus a systemic physical exam finding of hypervolemia
                  (peripheral edema, ascites, or pulmonary edema on auscultation)

               -  in the absence of pulmonary artery catheterization data 2 of the following signs
                  or symptoms: peripheral edema, ascites, jugular venous pressure &gt; 10mmHg,
                  orthopnea, paroxysmal nocturnal dyspnea, 5-pound weight gain, or signs of
                  congestion on chest x-ray or lung ultrasound

          -  Planned use of IV loop diuretic therapy during current hospitalization

          -  eGFR &gt; 30 ml/min/1.73m2 by the MDRD equation

          -  History of type 2 diabetes or a new hemoglobin A1c &gt; 6.5% this admission

        Exclusion Criteria:

          -  Type 1 diabetes

          -  Serum glucose &lt; 80mg/dl at enrollment

          -  Systolic blood pressure &lt; 90mmHg at enrollment

          -  Requirement of intravenous inotropic therapy

          -  History of hypersensitivity to any SGLT2 inhibitors

          -  Women who are pregnant or breastfeeding

          -  Severe anemia (Hemoglobin &lt; 7.5g/dl)

          -  Severe uncorrected aortic or mitral stenosis

          -  Inability to perform standing weights or measure urine output accurately

          -  History of diabetic ketoacidosis

          -  Scheduled combination nephron blockade with loop and thiazide therapy as an outpatient

          -  Diffuse anasarca with 4+ edema and projected hypervolemia exceeding 40-pounds

          -  Severe hepatic impairment (Child-Pugh class C)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JoAnn Lindenfeld, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sean Collins, MD</last_name>
    <phone>615-936-0087</phone>
    <email>sean.collins@vumc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zachary Cox, Pharm.D.</last_name>
    <phone>615-343-3473</phone>
    <email>zachary.l.cox@vumc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gabriel Hernandez, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>TriStar Centennial Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>A. Thomas McRae, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Thomas West Hospital</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mark Aaron, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sean Collins, MD</last_name>
      <phone>615-936-0087</phone>
      <email>sean.collins@vumc.org</email>
    </contact>
    <contact_backup>
      <last_name>Zachary Cox, Pharm.D.</last_name>
      <phone>615-343-3473</phone>
      <email>zachary.l.cox@vumc.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Adams KF Jr, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT, Berkowitz RL, Galvao M, Horton DP; ADHERE Scientific Advisory Committee and Investigators. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005 Feb;149(2):209-16.</citation>
    <PMID>15846257</PMID>
  </reference>
  <reference>
    <citation>Chioncel O, Mebazaa A, Maggioni AP, Harjola VP, Rosano G, Laroche C, Piepoli MF, Crespo-Leiro MG, Lainscak M, Ponikowski P, Filippatos G, Ruschitzka F, Seferovic P, Coats AJS, Lund LH; ESC-EORP-HFA Heart Failure Long-Term Registry Investigators. Acute heart failure congestion and perfusion status - impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry. Eur J Heart Fail. 2019 Nov;21(11):1338-1352. doi: 10.1002/ejhf.1492. Epub 2019 May 24.</citation>
    <PMID>31127678</PMID>
  </reference>
  <reference>
    <citation>Damman K, Testani JM. The kidney in heart failure: an update. Eur Heart J. 2015 Jun 14;36(23):1437-44. doi: 10.1093/eurheartj/ehv010. Epub 2015 Apr 2. Review.</citation>
    <PMID>25838436</PMID>
  </reference>
  <reference>
    <citation>Echouffo-Tcheugui JB, Xu H, DeVore AD, Schulte PJ, Butler J, Yancy CW, Bhatt DL, Hernandez AF, Heidenreich PA, Fonarow GC. Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: Findings from Get With The Guidelines-Heart Failure registry. Am Heart J. 2016 Dec;182:9-20. doi: 10.1016/j.ahj.2016.07.025. Epub 2016 Aug 27.</citation>
    <PMID>27914505</PMID>
  </reference>
  <reference>
    <citation>Mebazaa A, Gayat E, Lassus J, Meas T, Mueller C, Maggioni A, Peacock F, Spinar J, Harjola VP, van Kimmenade R, Pathak A, Mueller T, Tavazzi L, Disomma S, Metra M, Pascual-Figal D, Laribi S, Logeart D, Nouira S, Sato N, Parenica J, Deye N, Boukef R, Collet C, Van den Berghe G, Cohen-Solal A, Januzzi JL Jr; GREAT Network. Association between elevated blood glucose and outcome in acute heart failure: results from an international observational cohort. J Am Coll Cardiol. 2013 Feb 26;61(8):820-9. doi: 10.1016/j.jacc.2012.11.054. Epub 2013 Jan 16.</citation>
    <PMID>23333145</PMID>
  </reference>
  <reference>
    <citation>Kosiborod M, Inzucchi SE, Spertus JA, Wang Y, Masoudi FA, Havranek EP, Krumholz HM. Elevated admission glucose and mortality in elderly patients hospitalized with heart failure. Circulation. 2009 Apr 14;119(14):1899-907. doi: 10.1161/CIRCULATIONAHA.108.821843. Epub 2009 Mar 30.</citation>
    <PMID>19332465</PMID>
  </reference>
  <reference>
    <citation>Cox ZL, Lai P, Lewis CM, Lindenfeld J. Change in admission blood glucose from chronic glycemic status in acute heart failure hospitalization and 30-day outcomes: A retrospective analysis. Int J Cardiol. 2020 Jan 15;299:180-185. doi: 10.1016/j.ijcard.2019.07.069. Epub 2019 Jul 23.</citation>
    <PMID>31395364</PMID>
  </reference>
  <reference>
    <citation>Packer M, O'Connor C, McMurray JJV, Wittes J, Abraham WT, Anker SD, Dickstein K, Filippatos G, Holcomb R, Krum H, Maggioni AP, Mebazaa A, Peacock WF, Petrie MC, Ponikowski P, Ruschitzka F, van Veldhuisen DJ, Kowarski LS, Schactman M, Holzmeister J; TRUE-AHF Investigators. Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure. N Engl J Med. 2017 May 18;376(20):1956-1964. doi: 10.1056/NEJMoa1601895. Epub 2017 Apr 12.</citation>
    <PMID>28402745</PMID>
  </reference>
  <reference>
    <citation>O'Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V, Heizer GM, Komajda M, Massie BM, McMurray JJ, Nieminen MS, Reist CJ, Rouleau JL, Swedberg K, Adams KF Jr, Anker SD, Atar D, Battler A, Botero R, Bohidar NR, Butler J, Clausell N, Corbalán R, Costanzo MR, Dahlstrom U, Deckelbaum LI, Diaz R, Dunlap ME, Ezekowitz JA, Feldman D, Felker GM, Fonarow GC, Gennevois D, Gottlieb SS, Hill JA, Hollander JE, Howlett JG, Hudson MP, Kociol RD, Krum H, Laucevicius A, Levy WC, Méndez GF, Metra M, Mittal S, Oh BH, Pereira NL, Ponikowski P, Tang WH, Tanomsup S, Teerlink JR, Triposkiadis F, Troughton RW, Voors AA, Whellan DJ, Zannad F, Califf RM. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med. 2011 Jul 7;365(1):32-43. doi: 10.1056/NEJMoa1100171. Erratum in: N Engl J Med. 2011 Aug 25;365(8):773. Wilson, W H [corrected to Tang, W H W].</citation>
    <PMID>21732835</PMID>
  </reference>
  <reference>
    <citation>Cox ZL, Lenihan DJ. Loop diuretic resistance in heart failure: resistance etiology-based strategies to restoring diuretic efficacy. J Card Fail. 2014 Aug;20(8):611-22. doi: 10.1016/j.cardfail.2014.05.007. Epub 2014 May 28. Review.</citation>
    <PMID>24879974</PMID>
  </reference>
  <reference>
    <citation>Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. Circulation. 2016 Sep 6;134(10):752-72. doi: 10.1161/CIRCULATIONAHA.116.021887. Epub 2016 Jul 28. Review.</citation>
    <PMID>27470878</PMID>
  </reference>
  <reference>
    <citation>Heise T, Seewaldt-Becker E, Macha S, Hantel S, Pinnetti S, Seman L, Woerle HJ. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes. Diabetes Obes Metab. 2013 Jul;15(7):613-21. doi: 10.1111/dom.12073. Epub 2013 Feb 17.</citation>
    <PMID>23356556</PMID>
  </reference>
  <reference>
    <citation>Testani JM, Brisco MA, Turner JM, Spatz ES, Bellumkonda L, Parikh CR, Tang WH. Loop diuretic efficiency: a metric of diuretic responsiveness with prognostic importance in acute decompensated heart failure. Circ Heart Fail. 2014 Mar 1;7(2):261-70. doi: 10.1161/CIRCHEARTFAILURE.113.000895. Epub 2013 Dec 30.</citation>
    <PMID>24379278</PMID>
  </reference>
  <reference>
    <citation>Palazzuoli A, Testani JM, Ruocco G, Pellegrini M, Ronco C, Nuti R. Different diuretic dose and response in acute decompensated heart failure: Clinical characteristics and prognostic significance. Int J Cardiol. 2016 Dec 1;224:213-219. doi: 10.1016/j.ijcard.2016.09.005. Epub 2016 Sep 10.</citation>
    <PMID>27657476</PMID>
  </reference>
  <reference>
    <citation>Lala A, McNulty SE, Mentz RJ, Dunlay SM, Vader JM, AbouEzzeddine OF, DeVore AD, Khazanie P, Redfield MM, Goldsmith SR, Bart BA, Anstrom KJ, Felker GM, Hernandez AF, Stevenson LW. Relief and Recurrence of Congestion During and After Hospitalization for Acute Heart Failure: Insights From Diuretic Optimization Strategy Evaluation in Acute Decompensated Heart Failure (DOSE-AHF) and Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARESS-HF). Circ Heart Fail. 2015 Jul;8(4):741-8. doi: 10.1161/CIRCHEARTFAILURE.114.001957. Epub 2015 Jun 3.</citation>
    <PMID>26041600</PMID>
  </reference>
  <reference>
    <citation>Kronmal RA. Spurious Correlation and the Fallacy of the Ratio Standard Revisited. J Roy Stat Soc a Sta. 1993;156:379-392.</citation>
  </reference>
  <reference>
    <citation>Walker SH, Duncan DB. Estimation of the probability of an event as a function of several independent variables. Biometrika. 1967 Jun;54(1):167-79.</citation>
    <PMID>6049533</PMID>
  </reference>
  <reference>
    <citation>Harrell FE. Regression Modeling Strategies: With Applications to Linear Models, Logistic and Ordinal Regression, and Survival Analysis, 2nd Edition. Springer Ser Stat. 2015.</citation>
  </reference>
  <reference>
    <citation>Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Ponikowski P, Unemori E, Voors AA, Adams KF Jr, Dorobantu MI, Grinfeld LR, Jondeau G, Marmor A, Masip J, Pang PS, Werdan K, Teichman SL, Trapani A, Bush CA, Saini R, Schumacher C, Severin TM, Metra M; RELAXin in Acute Heart Failure (RELAX-AHF) Investigators. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet. 2013 Jan 5;381(9860):29-39. doi: 10.1016/S0140-6736(12)61855-8. Epub 2012 Nov 7.</citation>
    <PMID>23141816</PMID>
  </reference>
  <reference>
    <citation>Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007 Mar 28;297(12):1319-31. Epub 2007 Mar 25.</citation>
    <PMID>17384437</PMID>
  </reference>
  <reference>
    <citation>Felker GM, Mentz RJ, Cole RT, Adams KF, Egnaczyk GF, Fiuzat M, Patel CB, Echols M, Khouri MG, Tauras JM, Gupta D, Monds P, Roberts R, O'Connor CM. Efficacy and Safety of Tolvaptan in Patients Hospitalized With Acute Heart Failure. J Am Coll Cardiol. 2017 Mar 21;69(11):1399-1406. doi: 10.1016/j.jacc.2016.09.004. Epub 2016 Sep 18.</citation>
    <PMID>27654854</PMID>
  </reference>
  <reference>
    <citation>Konstam MA, Kiernan M, Chandler A, Dhingra R, Mody FV, Eisen H, Haught WH, Wagoner L, Gupta D, Patten R, Gordon P, Korr K, Fileccia R, Pressler SJ, Gregory D, Wedge P, Dowling D, Romeling M, Konstam JM, Massaro JM, Udelson JE; SECRET of CHF Investigators, Coordinators, and Committee Members. Short-Term Effects of Tolvaptan in Patients With Acute Heart Failure and Volume Overload. J Am Coll Cardiol. 2017 Mar 21;69(11):1409-1419. doi: 10.1016/j.jacc.2016.12.035.</citation>
    <PMID>28302292</PMID>
  </reference>
  <reference>
    <citation>Chen HH, Anstrom KJ, Givertz MM, Stevenson LW, Semigran MJ, Goldsmith SR, Bart BA, Bull DA, Stehlik J, LeWinter MM, Konstam MA, Huggins GS, Rouleau JL, O'Meara E, Tang WH, Starling RC, Butler J, Deswal A, Felker GM, O'Connor CM, Bonita RE, Margulies KB, Cappola TP, Ofili EO, Mann DL, Dávila-Román VG, McNulty SE, Borlaug BA, Velazquez EJ, Lee KL, Shah MR, Hernandez AF, Braunwald E, Redfield MM; NHLBI Heart Failure Clinical Research Network. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. JAMA. 2013 Dec 18;310(23):2533-43. doi: 10.1001/jama.2013.282190.</citation>
    <PMID>24247300</PMID>
  </reference>
  <reference>
    <citation>Voors AA, Davison BA, Teerlink JR, Felker GM, Cotter G, Filippatos G, Greenberg BH, Pang PS, Levin B, Hua TA, Severin T, Ponikowski P, Metra M; RELAX-AHF Investigators. Diuretic response in patients with acute decompensated heart failure: characteristics and clinical outcome--an analysis from RELAX-AHF. Eur J Heart Fail. 2014 Nov;16(11):1230-40. doi: 10.1002/ejhf.170. Epub 2014 Oct 7.</citation>
    <PMID>25287144</PMID>
  </reference>
  <reference>
    <citation>ter Maaten JM, Dunning AM, Valente MA, Damman K, Ezekowitz JA, Califf RM, Starling RC, van der Meer P, O'Connor CM, Schulte PJ, Testani JM, Hernandez AF, Tang WH, Voors AA. Diuretic response in acute heart failure-an analysis from ASCEND-HF. Am Heart J. 2015 Aug;170(2):313-21. doi: 10.1016/j.ahj.2015.05.003. Epub 2015 May 9.</citation>
    <PMID>26299229</PMID>
  </reference>
  <reference>
    <citation>Valente MA, Voors AA, Damman K, Van Veldhuisen DJ, Massie BM, O'Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, Davison B, Cleland JG, Givertz MM, Bloomfield DM, Fiuzat M, Dittrich HC, Hillege HL. Diuretic response in acute heart failure: clinical characteristics and prognostic significance. Eur Heart J. 2014 May 14;35(19):1284-93. doi: 10.1093/eurheartj/ehu065. Epub 2014 Feb 28.</citation>
    <PMID>24585267</PMID>
  </reference>
  <reference>
    <citation>Ter Maaten JM, Valente MA, Damman K, Cleland JG, Givertz MM, Metra M, O'Connor CM, Teerlink JR, Ponikowski P, Bloomfield DM, Cotter G, Davison B, Subacius H, van Veldhuisen DJ, van der Meer P, Hillege HL, Gheorghiade M, Voors AA. Combining Diuretic Response and Hemoconcentration to Predict Rehospitalization After Admission for Acute Heart Failure. Circ Heart Fail. 2016 Jun;9(6). pii: e002845. doi: 10.1161/CIRCHEARTFAILURE.115.002845.</citation>
    <PMID>27266853</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 2, 2020</study_first_submitted>
  <study_first_submitted_qc>March 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2020</study_first_posted>
  <last_update_submitted>May 18, 2020</last_update_submitted>
  <last_update_submitted_qc>May 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Zachary L. Cox</investigator_full_name>
    <investigator_title>Co-Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol</mesh_term>
    <mesh_term>Diuretics</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

